BioCentury
ARTICLE | Clinical News

AM-Pharma completes Phase II enrollment of recAP in AKI

May 25, 2017 7:51 PM UTC

AM-Pharma B.V. (Bunnik, the Netherlands) completed enrollment of 301 patients in the Phase II STOP-AKI trial of recAP (recombinant alkaline phosphatase) to treat sepsis-associated acute kidney injury (AKI). The double-blind, placebo-controlled, international trial is evaluating the primary endpoint of creatinine clearance in patients receiving 0.4, 0.8 and 1.6 mg/kg IV recAP once daily for 3 days. Secondary endpoints include the incidence of renal replacement therapy (RRT) over 28 days, immunogenicity and quality of life (QOL). Data from the trial are expected in early 2018...

BCIQ Company Profiles

AM-Pharma B.V.

BCIQ Target Profiles

Lipopolysaccharide (LPS)